

CARDIOLOGY II PANEL

EDITORIAL BOARD LIAISON

Judy W.M. Cheng, Pharm.D., MPH,
FCCP, BCPS (AQ Cardiology)
Professor of Pharmacy Practice
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Department of Pharmacy
Brigham and Women's Hospital
Boston, Massachusetts

EVOLUTION OF ANTITHROMBOTIC THERAPY USED IN ACUTE CORONARY SYNDROMES

Author

Sarah A. Spinler, Pharm.D., FCCP,
FAHA, BCPS (AQ Cardiology)
Professor of Clinical Pharmacy
Department of Pharmacy Practice
and Pharmacy Administration
Philadelphia College of Pharmacy
University of the Sciences in Philadelphia
Philadelphia, Pennsylvania

Reviewers

Michael P. Dorsch, Pharm.D., M.S.,
BCPS (AQ Cardiology)
Clinical Pharmacist, Cardiology
Adjunct Clinical Assistant Professor
Department of Pharmacy and College of Pharmacy
University of Michigan
Ann Arbor, Michigan

Kerry K. Pickworth, Pharm.D.
Specialty Practice Pharmacist – Cardiology
Associate Professor of Clinical Pharmacy
Department of Pharmacy
The Ohio State University Medical Center
Columbus, Ohio

Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS
Clinical Pharmacy Specialist, Infectious Diseases
Patient Support Service
Veterans Affairs Medical Center
West Palm Beach, Florida
Clinical Assistant Professor of Pharmacy Practice
University of Florida College of Pharmacy
Gainesville, Florida

ATRIAL AND VENTRICULAR ARRHYTHMIAS: EVOLVING PRACTICES

Author

Cynthia A. Sanoski, Pharm.D., FCCP, BCPS
Department Chair
Associate Professor
Department of Pharmacy Practice
Jefferson School of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Reviewers

Steven A. Baroletti, Pharm.D., BCPS
Clinical Practice Manager
Department of Pharmacy
Brigham and Women's Hospital
Boston, Massachusetts

Lynette Moser, Pharm.D.
Clinical Assistant Professor
Department of Pharmacy Practice
Wayne State University
Clinical Specialist – Cardiology
Department of Pharmacy Services
Harper University Hospital
Detroit, Michigan

Jeffrey T. Sherer, Pharm.D., MPH, BCPS
Clinical Associate Professor
Department of Clinical Sciences and Administration
University of Houston College of Pharmacy
Houston, Texas

PERIOPERATIVE MANAGEMENT OF ANTITHROMBOTIC THERAPY

Authors

Jeremy D. Flynn, Pharm.D., BCPS
Clinical Pharmacist Specialist/Cardiothoracic Surgery
Department of Pharmacy Services
UK Healthcare
Assistant Adjunct Professor
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky

Kevin W. Hatton, M.D.
Assistant Professor
Associate Residency Program Director
Department of Anesthesiology
University of Kentucky College of Medicine
Lexington, Kentucky

Reviewers

William E. Dager, Pharm.D., FCCP, FCSHP, FCCM, BCSP
Pharmacist Specialist
University of California, Davis Medical Center
Clinical Professor of Medicine
UC Davis School of Medicine
Sacramento, California
Clinical Professor of Pharmacy
UC San Francisco School of Pharmacy
San Francisco, California
Clinical Professor of Pharmacy
Touro School of Pharmacy
Vallejo, California

Clarence Chant, Pharm.D., FCCP, FCSHP, BCPS
Clinical Pharmacy Specialist
Critical Care/Research, Pharmacy Department
St. Michael's Hospital
Assistant Professor
Leslie Dan Faculty of Pharmacy
University of Toronto
Toronto, Ontario, Canada

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 1, Cardiology II chapters:

H. Gwen Bartlett, Pharm.D., BCPS
Clinical Pharmacist II
Department of Pharmacy
St. Francis Health Center
Topeka, Kansas

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

Mary Lee, Pharm.D., FCCP, BCPS
Vice President and Chief Academic Officer
Pharmacy and Health Sciences Education
Midwestern University
Professor of Pharmacy Practice
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Marilyn M. Barbour (New England Research Institute); Steven A. Baroletti (Sanofi-aventis); Michael A. Crouch (ARCA biopharma); Paul Dobesh (Sanofi-aventis, Eli Lilly, Inc., CV Therapeutics); Michael Dorsch (Merck); Shannon Willhite Finks (Novartis Pharmaceuticals); Jeremy D. Flynn (The Medicines Co., Novo Nordisk); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid); Heath R. Jennings (American Heart Association); Lynette Moser (Michigan Department of Community Health); Kerry K. Pickworth (The Medicines Co., Merck, ARCA biopharma); Brian J. Quilliam (Ortho-McNeil Janssen); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, *Annals of Pharmacotherapy*); Jeffrey T. Sherer (Sturge-Weber Foundation); Evan Sisson (American Association of Diabetes Educators, University of Pittsburgh School of Pharmacy, Novartis Pharmaceuticals); Anne P. Spencer (ARCA biopharma); Sarah A. Spinler (Xcenda, Sanofi-aventis); Zachary A. Stacy (Sanofi-aventis, CV Therapeutics)

Stock Ownership: Katherine H. Chessman (Procter & Gamble [stock owned by spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Emilie Karpiuk (Cardinal Health); Michelle Richardson (TEI Biosciences [stock owned by spouse or significant other])

Royalties: Lisa C. Hutchison (ASHP)

Grants: Kai I. Cheang (NIH NICHD); Judy W.M. Cheng (St. Jude's Medical Research Center); Nathan Clark (Sanofi-aventis); Amy M. Franks (Pfizer); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Cynthia Jackevicius (ACCP, CIHR [two grants]); Brian J. Quilliam (Takeda Pharmaceuticals North America); Michelle Richardson (NIH NIDDK [two grants]); Nancy L. Shapiro (University of Illinois – Chicago Vahlteich Award); Anne P. Spencer (Pfizer)

Honoraria: Nathan Clark (McMaster University, University of New Mexico, University of Colorado School of Pharmacy); Michael A. Crouch (The Medicines Co., Ortho-McNeil), Paul Dobesh (Sanofi-aventis); Michael Dorsch (Sanofi-aventis); Jeremy D. Flynn (The Medicines Co.); Kerry K. Pickworth (The Medicines Co.); Michelle Richardson (Amgen); Evan Sisson (Novartis Pharmaceuticals); Sarah A. Spinler (Sanofi-aventis, GlaxoSmithKline); Zachary A. Stacy (Sanofi-aventis)

Nothing to Disclose: Adam J. Bursua, Benita Busch, Clarence Chant, Terri S. Cook, William E. Dager, Mary Beth Dowd, Sipi Garg, Kevin W. Hatton, Matthew K. Ito, Marianne McCollum, Mindi S. Miller, Kari L. Olson, Cynthia A. Sanoski, Ross T. Tsuyuki, Benjamin W. Van Tassell, Daniel M. Witt

ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmaceutical Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmaceutical Specialties is an autonomous certification agency of the American Pharmacists Association. BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm. Other questions regarding recertification should be directed to:

Board of Pharmaceutical Specialties
2215 Constitution Avenue, NW
Washington, DC 20037
(202) 429-7591
www.bpsweb.org